8517 Phase I results from an open-label, randomized,...

8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

Brümmendorf, T., Guigay, J., Mesía, R., Trigo, J., Keilholz, U., Dittrich, C., Kerber, A., Picard, M., Vermorken, J.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71608-8
Date:
September, 2009
File:
PDF, 72 KB
english, 2009
Conversion to is in progress
Conversion to is failed